Viva Biotech Holdings Past Earnings Performance
Past criteria checks 0/6
Viva Biotech Holdings's earnings have been declining at an average annual rate of -32.4%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 41.6% per year.
Key information
-32.4%
Earnings growth rate
-32.6%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 41.6% |
| Return on equity | -2.7% |
| Net Margin | -5.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Viva Biotech Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,156 | -116 | 418 | 128 |
| 30 Sep 23 | 2,284 | -276 | 417 | 150 |
| 30 Jun 23 | 2,413 | -436 | 416 | 172 |
| 31 Mar 23 | 2,396 | -482 | 413 | 154 |
| 31 Dec 22 | 2,380 | -528 | 410 | 136 |
| 30 Sep 22 | 2,283 | -209 | 398 | 116 |
| 30 Jun 22 | 2,186 | 111 | 385 | 96 |
| 31 Mar 22 | 2,145 | 199 | 353 | 94 |
| 31 Dec 21 | 2,104 | 288 | 322 | 92 |
| 30 Sep 21 | 1,815 | 258 | 271 | 87 |
| 30 Jun 21 | 1,526 | 228 | 219 | 81 |
| 31 Mar 21 | 1,111 | -79 | 171 | 74 |
| 31 Dec 20 | 697 | -387 | 123 | 66 |
| 30 Sep 20 | 538 | -349 | 96 | 59 |
| 30 Jun 20 | 378 | -311 | 70 | 52 |
| 31 Mar 20 | 351 | -23 | 62 | 48 |
| 31 Dec 19 | 323 | 266 | 55 | 45 |
| 30 Sep 19 | 299 | 176 | 48 | 37 |
| 30 Jun 19 | 275 | 86 | 42 | 30 |
| 31 Mar 19 | 243 | 88 | 36 | 27 |
| 31 Dec 18 | 210 | 91 | 30 | 25 |
| 31 Dec 17 | 148 | 76 | 17 | 17 |
| 31 Dec 16 | 96 | 24 | 14 | 17 |
Quality Earnings: VBIZ.F is currently unprofitable.
Growing Profit Margin: VBIZ.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VBIZ.F is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.
Accelerating Growth: Unable to compare VBIZ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VBIZ.F is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).
Return on Equity
High ROE: VBIZ.F has a negative Return on Equity (-2.71%), as it is currently unprofitable.